Results: 20 eyes of 20 patients with RCE caused by trauma (n = 14), anterior basement membrane dystrophy (n = 5) or idiopathic (1) were studied. The mean age of patients was 44 years and mean ...

This trial marks the world's first clinical study of an in vivo CRISPR-Cas ribonucleoprotein (RNP)-based genome editing investigational therapy for TGFBI corneal dystrophy.

This trial marks the world's first clinical study of an in vivo CRISPR-Cas ribonucleoprotein (RNP)-based genome editing investigational therapy for TGFBI corneal dystrophy.

Other studies in culture have implicated Dgs in basement membrane assembly 6, 7, 8 as well as in agrin-induced aggregation of AChRs in myotubes 3, 4.

By MATTHEW PERRONE, Associated Press WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for ...

GenEditBio Limited has announced the first patient has been dosed in an investigator-initiated trial (IIT) of GEB-101, an in vivo genome editing program for TGFBI corneal dystrophy. TGFBI corneal ...

Clinical outcome was evaluated as defined by Maharajan et al. [23] The objective of the ProKera was one or more of the following: to promote epithelialization, to prevent corneal perforation, to ...

With improved nutrition, the cornea will start becoming clear once the new transplanted stem cells start repopulating,” said Joshi. He explained the procedure of a stem cell transplant of the eye.